Orphan designation: imatinib Treatment of pulmonary arterial hypertension, 21/06/2021 Positive

Overview

Metadata
Provider: 
European Medicines AgencyEuropean Medicines Agency
URL: 
https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2449https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2449
Retrieved on: 
Tuesday, April 9, 2024
Information
Tags: 
Community, Diagnosis, Civil service commission, Enzyme, Prevalence, Cell, Disease, Patient, Committee, Cancer, EMA, IRIS, Imatinib, Orthostatic hypertension, Agency, European, COMP, European Commission, MDC, PAH, Marketing, FGK, Medicine, Pharmaceutical industry
Geotags: 
EUROPEAN UNION, RARE, EU
Summary
Key Points: 
  • Overview
    This medicine was designated as an orphan medicine for the treatment of pulmonary arterial hypertension (PAH) in the European Union on 21 June 2021.
  • All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.
  • The full list of orphan designations is available in the Community register of orphan medicinal products for human use.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:
Copyright: 
2024 European Medicines Agency. All Rights Reserved.